Onasemnogene Abeparvovec, Nusinersen, and Risdiplam are approved for the treatment of symptomatic or presymptomatic SMA patients with 2-copy SMN2 [5]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.